GET DAILY SIGNALSWhy Is Vir Biotechnology (VIR) Stock Down -15.10% Today?
Key Takeaways
- VIR shares fell 15.10% to $10.29 in the opening minutes of Friday's session, down from Thursday's close of $12.12.
- The primary catalyst is the pricing of a $150 million underwritten offering of 15 million shares at $10.00 each, a 17.5% discount to the prior close.
- New stock equals roughly 9% of the 171.3 million shares outstanding, with a 30-day option covering 2.25 million additional shares.
- Net proceeds are earmarked for pre-commercial launch work on the hepatitis delta program, the T-cell engager oncology platform, and general corporate purposes.
- Secondary pressure came from a soft biotech tape, with sector benchmarks lower while broad equity indices edged higher.
- News Significance Score: 65/100 — A major discounted financing met a move nearly five times the stock's typical daily swing.
- Traders are watching whether the $10.00 offering price acts as a floor through the expected November 16 closing.
- Deeper context on VIR Price Targets, Earnings, and Forecast data is available on dedicated pages — explore them for a fuller picture.
- Explore Trending AI Robots to see which automated strategies are performing best in the current market.
Opening Summary
Vir Biotechnology, Inc. (VIR) is a San Francisco-based clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer, including the hepatitis delta combination of elebsiran and tobevibart and a portfolio of dual-masked T-cell engagers built on its PRO-XTEN technology. The stock fell 15.10% to $10.29 shortly after Friday's opening bell, compared with the previous session's close of $12.12 — a decisive move lower. The immediate cause is unambiguous: after Thursday's close, Vir priced a $150 million follow-on offering at $10.00 per share, well below the market price, and the shares repriced toward that level.
A $150 Million Offering at a Deep Discount
The company sold 15 million common shares at $10.00 each for gross proceeds of roughly $150 million. That price is 17.5% below Thursday's $12.12 close, and secondary-market investors quickly marked the stock to the deal. The raise adds about 9% to a share count of approximately 171.3 million, and underwriters — Leerink Partners, Morgan Stanley and Evercore ISI, with Raymond James as co-manager — hold a 30-day option on up to 2.25 million further shares, a potential additional overhang. For a clinical-stage company whose value rests on future pipeline cash flows, equity issuance directly dilutes the claim of existing holders, and a double-digit discount signals the clearing price underwriters needed to place the size. Closing is expected November 16.
Capital for a Post-Data Launch Build-Out
The timing is deliberate. Vir's shares had already roughly doubled year to date before this week, and on Monday they jumped about 12% to $13.645 after the pivotal ECLIPSE 1 trial of elebsiran plus tobevibart met its primary and key secondary endpoints in chronic hepatitis delta — 44% of treated patients achieved undetectable virus with ALT normalization at week 48 versus none in the delayed-treatment arm. The company now plans a mid-2027 FDA submission and is funding pre-commercial activity ahead of that filing, while advancing its oncology platform. The offering also follows a licensing arrangement with GILD covering three solid-tumor candidates. Raising capital into strength after a clinical win is a standard biotech playbook, but it does not prevent the dilution repricing that follows.
Analyst Targets and the New Price Anchor
There were no downgrades behind the decline. Price objectives were lifted after the trial readout, with several firms moving into the mid-to-high $20s and the consensus sitting near $24 — levels that now look distant. The market's near-term reference point has instead become the $10.00 offering price, and shares are trading modestly above it. The stock has also slipped below both its 20-day and 50-day moving averages.
Market Context and Trading Activity
Volume was heavy from the opening bell, running well above a three-month average pace of roughly 1.1 million shares a day. The move was overwhelmingly idiosyncratic: biotech sector benchmarks were down modestly in early trade while the S&P 500 traded slightly higher, and hepatitis delta rival MIRM was roughly flat. Support is often cited near $8.50 and resistance near $12.00, within a 52-week range of $5.32 to $14.38. Trading near $10.29, the shares sit about 15% below their recent 20-day average.
News Significance Score
The score runs from 0 — no meaningful news and a move that is normal for the stock — to 100, meaning transformative news and an extreme, rare price move. This event lands at 65 out of 100. The verified news is substantial rather than transformative: a $150 million equity raise priced 17.5% below the last close is material financing for a company valued near $1.8 billion, but it does not alter the underlying clinical story. The decline was close to five times VIR's typical daily swing of about 3%, and no session in the past 60 produced a larger one-day move. Strong news plus a rare move combine into that mid-to-high score.
What Comes Next for VIR
Attention shifts to the November 16 settlement of the offering and whether the $10.00 price holds as a base. Operationally, the calendar is dense: topline data from the ECLIPSE 2 switch study and the ECLIPSE 3 head-to-head trial against bulevirtide are expected in the first quarter of 2027, ahead of a planned FDA submission in mid-2027. Pivotal work for the prostate cancer candidate VIR-5500 is slated to begin in 2027. Risks include further capital needs if launch costs run high, competitive pressure from established and emerging hepatitis delta therapies, and the possibility that the added share supply keeps a lid on the stock until the deal clears.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated view of the platform's strongest automated strategies under present market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the top performers are featured here. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the list changes as conditions shift. Review the current lineup to see which approaches are working right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
VIR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for VIR turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 66 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 129 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 53 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases
Industry Biotechnology
Advertisement